14 publications
| Name | Date | Type | Actions |
|---|---|---|---|
SALES 1st quarter 2024: €134M The Vetoquinol Group recorded sales of €133.7 million in the 1st quarter of fiscal 2024, including €83.4 million for Essential products. |
29/04/2024 | Public releases | |
Availability of the 2023 universal registration document On 24 April 2024, Vetoquinol filed its 2022 Universal Registration Document with the Autorité des Marchés Financiers (AMF) in ESEF (European Single Electronic Format). |
24/04/2024 | Public releases | |
2023 ANNUAL RESULTS Annual sales: €529m (stable at constant exchange rates) |
20/03/2024 | Public releases | |
Annual sales 2023: €529 million Annual Sales of Essential products: €313 million (up 4.5% at constant exchange rates) |
24/01/2024 | Public releases | |
Vétoquinol continues to launch reference products Lure (France), December 16, 2013 – In line with its strategy of developing products targeting fast-growing markets, the Vétoquinol Group expands its Flexadin® range world-wide and launches Zylkène® in the United States. |
16/12/2013 | Public releases | |
2013 3rd quarter sales show organic growth Vétoquinol generated sales of €74.0 million in the 3rd quarter of 2013, a drop of 0.1% based on reported data, and a 4.4% increase at constant exchange rates. |
24/10/2013 | Public releases | |
First half Results 2013 Half year results |
09/09/2013 | Half Year Report | |
Half year financial report 2013 2013 Half year Financial Report |
30/08/2013 | Half Year Report | |
The reference products demonstrate solid growth Lure (France), August 29, 2013 – At its meeting on August 27, 2013, the Vétoquinol S.A. Board of Directors reviewed the Group’s results, and approved the financial statements for the first six months of 2013. |
29/08/2013 | Public releases | |
Q2 2013 sales Vétoquinol posted Q2 2013 sales of €70 million, up 0.3% on reported figures and up 1.4% like for like. |
16/07/2013 | Public releases |